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 Abstract 
Background: Pelvic floor muscle training (PFMT) in women seeking treatment for prolapse reduces 
prolapse severity and symptoms. PFMT may also be effective in secondary prevention of prolapse 
and the need for future treatment.  
 
Methods: We conducted a parallel-group, multicentre, randomised controlled trial in women from a 
longitudinal study of pelvic floor function after childbirth. Eligible women had stage I to III prolapse 
but had not sought treatment. Those with major stages of prolapse (stage IV), or no prolapse (stage 
0), were excluded. Women were randomly assigned (1:1), by remote computer allocation, to receive 
one-to-one PFMT (five physiotherapy appointments over 16 weeks, and annual review) plus Pilates-
based PFMT classes and a DVD for home use (intervention group), or a lifestyle advice leaflet for 
women with prolapse (control group). Women and intervention physiotherapists could not be 
blinded to treatment. The primary outcome was self-report of prolapse symptoms (Pelvic Organ 
Prolapse Symptom Score, POP-SS) at two years, with lower scores indicating fewer symptoms. 
 
Findings: 414 women were randomised (207 intervention, 207 control), with one post-
randomisation exclusion per group (206 per group analysed). At baseline, 97% of women had 
prolapse above or at the hymen. Mean POP-SS score at two years was 3·2 (SD 3·4) for the 
intervention group, significantly lower than the control group (mean 4·2 (SD 4·4)), adjusted mean 
difference -1·01 (95% CI −1·70 to −0·33). The mean symptom score stayed similar across time-points 
in the control group, but decreased in the intervention group. Uptake of further treatment for 
prolapse within two years was less common in the intervention group (5·9% vs 14·4%, OR=0·29 (95% 
CI 0·12 to 0·71), p=0·007). Three adverse events occurred in the intervention group (one fall, one 
pain in tail bone, one chest pain and shortness of breath). 
 
Interpretation: We provide evidence that PFMT leads to a small, but likely important reduction in 
prolapse symptoms, and lower uptake of prolapse treatment. This is important information for 
women and caregivers considering preventive strategies. 
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 Introduction 
Pelvic organ prolapse is the symptomatic descent of one or more of the anterior vaginal wall, 
posterior vaginal wall, the uterus (cervix), or the apex of the vagina from the normal anatomical 
position,1 caused by herniation through deficient pelvic fascia, or weaknesses or deficiencies in the 
ligaments or muscles which should support the pelvic organs. Associated symptoms include a 
sensation of vaginal bulge, something coming down, urinary, bowel and sexual dysfunction, and 
backache. In one study of 27,000 post-menopausal women, 40% had some degree of prolapse.2 A 
woman’s lifetime risk of undergoing surgery for prolapse or related urinary incontinence has been 
estimated as 7% and 11%.3 In 2012-13 in England, 35,094 women were admitted to hospital with a 
main diagnosis of female genital prolapse with 29,618 operations performed4. 
 
Pelvic floor muscle training (PFMT) is often recommended for prolapse treatment, and theoretically 
may prevent prolapse progressing and becoming symptomatic. Borello-France5 found women with 
stage II prolapse (within +/- 1 cm of the hymen) were better able to elevate their pelvic floor than 
those with stage III or IV prolapse, and hypothesised that weak pelvic floor muscles (PFMs) may be a 
contributory factor in preventing prolapse development. However the lack of trials evaluating the 
role of PFMT in prolapse prevention has been highlighted.6 Conversely clear evidence of the clinical 
and cost-effectiveness of PFMT in the treatment of established prolapse is now available from two 
recent randomised controlled trials (RCT).7,8  
 
PREVPROL, a secondary prevention trial,9 aimed to determine clinical and cost-effectiveness of PFMT 
to prevent prolapse symptoms, worsening prolapse severity and uptake of prolapse treatment. This 
paper specifically reports symptoms and uptake of treatment in the first two years. We plan to 
report longer-term outcomes, including prolapse severity, when data become available. 
 
Methods 
Study design and participants 
This was a three-centre (Dunedin New Zealand, Aberdeen and Birmingham UK), parallel-group RCT 
(1:1 allocation) of PFMT versus control (prolapse lifestyle advice leaflet) in the secondary prevention 
of prolapse. Participants had been involved in a longitudinal study of women after an index birth 
occurring between October 1993 to September 1994 (ProLong).10 At 12 year follow-up these women 
were invited to have a POP-Q (Pelvic Organ Prolapse Quantification) examination to assess for 
prolapse.11 
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 Women with anatomical evidence of prolapse (POP-Q stage ≥ I), who had not sought prolapse 
treatment were potentially eligible. Women were excluded if they had stage 0 or IV prolapse; 
previous incontinence surgery (except mid-urethral sling operation); previous formal instruction in 
PFMT for any diagnosis in preceding five years; were planning pregnancy, pregnant, or delivered a 
baby within the last six months; or unable to give informed consent. 
 
Recruitment to the trial focused on those women who had agreed to have a POP-Q at 12 year 
follow-up in ProLong. In New Zealand (NZ), all such women were asked to complete a baseline 
questionnaire and, if eligible on the basis of their response, to attend for a further POP-Q. In the UK, 
it was not feasible to undertake a further POP-Q for every woman, therefore we used the 12 year 
POP-Q findings and baseline questionnaire responses to confirm eligibility. A small number of UK 
women who agreed to a POP-Q, but had not been examined at 12 years, were invited for POP-Q 
assessment if they were eligible based on their baseline questionnaire responses.  
 
POP-Qs were carried out in Aberdeen by authors CG and CH, and a nurse and physiotherapist trained 
to competency by CG; in Birmingham by author PTH, one other experienced urogynaecologist and a 
POP-Q-trained urogynaecology trainee; and in NZ by author DW and two other gynaecologists 
trained to competency by DW. 
 
Randomisation and blinding 
Group allocation was generated by a researcher using a password-protected computer program at 
the Trial Office. Group allocation used minimisation based on: centre, parity (≤3 deliveries versus 
>3), prolapse stage (above hymen versus at/beyond hymen), and delivery method (any vaginal 
versus all Caesarean Sections). Women were informed of their group by letter. Treatment could not 
be concealed from women as the intervention involved attendance at appointments and classes, 
and daily home exercises. Outcome assessment was by participant-completed postal questionnaires 
administered at baseline (when randomised), one and two years after randomisation. Researchers 
conducting data entry were blinded to group allocation. Analysis was conducted by a statistician (AE) 
blinded to group allocation until after the database was closed. 
 
Procedures 
The intervention consisted of PFMT delivered both one-to-one and in a class setting. Women were 
offered five appointments with a specialist women’s health physiotherapist (intervention 
physiotherapist) over 16 weeks (weeks 0, 2, 6, 11 and 16), who assessed pelvic floor muscles, taught 
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 correct exercise technique, prescribed individualised home PFMT programme (three sets of 
exercises daily, completion of exercise diaries), provided a prolapse lifestyle advice leaflet (focusing 
on weight loss, avoidance of heavy lifting, constipation, coughing, and high-impact exercise), and 
tailored lifestyle advice (Phase 1). Intervention group women were then offered modified Pilates 
classes (with pelvic floor muscle exercises as a key distinct element and an exercise DVD12 for home 
use), and a one-to-one physiotherapy review appointment one and two years after randomisation 
(Phase 2). Classes were led by specialist women’s health physiotherapists trained in Pilates and took 
place in six-week blocks; each woman was offered two blocks. In NZ, women were offered 
attendance at existing weekly Pilates exercise classes, led by physiotherapists similarly trained to 
those in the UK, at the University of Otago School of Physiotherapy clinics, open also to women in 
the general public.  
 
Control group women received, by post, the same prolapse lifestyle advice leaflet as the 
intervention group.  
 
All adverse and serious adverse events were recorded on an Adverse Event Form and reported 
immediately to the Trial Office in terms of seriousness, relatedness to the intervention and any 
changes made to the treatment. 
 
The primary outcome was prolapse symptom severity (Pelvic Organ Prolapse Symptom Score, POP-
SS)13 at two years. POP-SS is a validated, patient-completed questionnaire with seven items 
addressing frequency of prolapse symptoms in the previous four weeks; each item is scored from 0 
(never) to 4 (all of the time), with a total ranging from 0-28. Secondary outcomes were prolapse-
related quality of life (single item measures scored 0-10, adapted from the International 
Consultation on Incontinence Questionnaire-Vaginal Symptoms (ICIQ-VS)14); and use of primary and 
secondary care health services for prolapse symptoms. Other outcomes were self-reported health 
and well-being using a 12-item short form survey (SF-12)15; lifestyle changes8; urinary leakage 
(including ICIQ-Urinary Incontinence (ICIQ-UI) short-form16, ranging from 0-21, higher score 
indicating greater severity), bowel symptoms (ICIQ-Bowel Symptoms - early short-form version), 
sexual symptoms (including the short-form Prolapse Incontinence Sexual Questionnaire (PISQ-12)17, 
ranging from 0-48, higher scores indicating greater sexual dysfunction); PFM exercise adherence; 
and a rating of health benefit (better, same, worse). 
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 Sample size calculations indicated that 200 per group would provide over 99% power at a 5% 
significance level (two-sided) to detect a difference of 3 in POP-SS scores (standard deviation of 7 
assumed) between groups. This was based on the difference observed in our pilot trial of PFMT for 
treatment of prolapse.18 allowing for 10% loss to follow-up. 
 
 
Statistical analysis 
Participants with follow-up data were included in the analysis according to the group to which they 
had been randomised, whether or not they received their allocated intervention.  POP-SS scores 
were compared using repeated measures mixed models with compound symmetry covariance 
matrices. Other continuous outcomes were analysed using analysis of covariance, and binary/ordinal 
outcomes were analysed using binary/ordinal logistic regression. All analyses adjusted for age, 
minimisation variables and baseline measurements. Assumptions of linearity and normality of error 
distributions were examined by inspection of residual plots in the mixed models and analyses of 
covariance, and score tests were performed to examine the proportional odds assumptions in the 
ordinal models. These assumptions were shown to hold. 
 
Sensitivity analyses were conducted to examine the effect of missing POP-SS data under various 
assumptions.  We first assumed that missing data were missing at random using multiple 
imputation, with subsequent assumptions that data were missing not at random.  Missing data were 
assumed to be better than expected (one point lower than the imputed value assuming missing at 
random, and similarly one point worse than expected.  We also restricted these assumptions of 
being better and worse to each arm individually. 
 
Sub-group analyses of treatment interactions with age (<50/50 years+), prolapse stage (above or at 
the hymen/beyond hymen)19, and leading edge of prolapse (anterior/posterior/both) were 
undertaken.  
 
In the economic evaluation, the SF-12 data were converted to SF-6D using an algorithm from the 
University of Sheffield (www.shef.ac.uk/scharr/sections/heds/mvh/sf-6d), to allow the estimation of 
a preference-based single index measure for health using UK population values.20 SF-6D scores were 
averaged and used to calculate the cost per QALY at years one and two. The cost of the intervention 
was calculated using the Department of Health Reference Costs for 2011/12 (www.gov.uk).  
 
Statistical analysis was conducted, using Stata v13 (StataCorp, College Station, TX, USA).  
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Role of funding source 
Study sponsors had no role in design, data collection, analysis, interpretation, or writing of the 
report. AE, SH, and MC had access to trial data and all authors had final responsibility for the 
decision to submit for publication. 
  
Results 
 
Between November 2008 and February 2009 in NZ (14 to 15 years after index birth), and October 
2010 and February 2011 in the UK (16 to 17 years after index birth), 1130 women were invited to 
consider taking part in the trial. Five hundred and forty-four women responded to the baseline 
questionnaire, of whom 130 were ineligible, declined or did not attend for examination. In total, 414 
women were randomised between December 2008 and February 2010 (NZ, n=77), and October 
2010 and September 2011 (UK, n=337): 207 to intervention, 207 to control. Two women were 
subsequently found to be ineligible (one intervention, one control) and treated as post-
randomisation exclusions, leaving 412 women for inclusion in analysis (Figure 1). 
 
Baseline characteristics are summarised by randomised group in Table 1. Ninety-seven percent 
(399/412) of women had prolapse above or at the level of the hymen (186/412, 45% stage I, 
213/412, 52% stage II above or at the hymen).  
 
The return rate of questionnaires was 79% at one year and 84% at two years. In the intervention 
group 74% of women attended three or more of the five appointments offered, 9% (19) attended no 
appointments, 44% (88) attended all five (mean 3·5 appointments, SD 1·7), and 65% returned all 
their home exercise diaries. Attendance rate at annual physiotherapy review appointments was 52% 
and 45% at year 1 and year 2 respectively, and uptake of classes was 28% and 15% at first and 
second block respectively. At year 2, 77% of women in the intervention group reported they had 
done PFM exercises in the last four weeks, which was significantly higher than in the control group 
(53%) (OR 3·22, 95% CI 1·94–5·32, p<0·001). 
 
Three adverse events were reported; all in the intervention group. One woman had a fall the day 
before attending a Pilates class, one experienced pain in her tail bone during PFMT, and one 
experienced shortness of breath and chest pain during PFMT. 
 
8 
 
 Primary outcome measure 
There was a significantly lower POP-SS score at two years in the intervention group compared to the 
control group (mean difference −1·01, 95% CI (−1·70 to −0·33), p=0·004) (Table 2), indicating fewer 
symptoms. The difference at one year was also significant in favour of the intervention group (mean 
difference −0·98, 95% CI (−1·61 to −0·35), p=0·002) (Table 2). Sensitivity analyses to examine the 
effect of missing POP-SS scores gave estimates of the differences between the groups which were 
significant and similar to those from the original model, ranging from −1.03 to −0.70 at two years. No 
significant sub-group interaction effects were found. 
 
Other prolapse-related outcomes 
The individual POP-SS symptoms significantly more common in the control group at two years were 
‘a feeling of something coming down from or in your vagina’ and ‘a need to strain (push) to empty 
your bladder’ (Table 3). The prevalence of these symptoms tended to decrease over time in the 
intervention group, but stayed constant in the control group. Overall, the symptom most commonly 
reported by both groups was ‘a feeling that your bowel has not emptied completely’ (Table 4). 
 
Women in the intervention group were more likely to say they felt a health-related benefit from the 
study compared to controls (44·2% vs 9·8%, OR=7.0 (95% CI 3.9 to 12.8), p<0·001). 
 
There were no significant differences at two years between groups in quality of life associated with 
prolapse symptoms in any domain (Table 5). 
 
Further treatment for prolapse symptoms within the 2 year follow-up was less common in the 
intervention group (5·9% vs 14·4%, OR=0·29 (95% CI 0·12 to 0·71), p=0·007). Specifically, the rate of 
GP consultations relating to prolapse symptoms was lower in the intervention group (2·9% vs 12·2%, 
OR=0·19 (95% CI 0·05 to 0·67), p=0·010) (Table 6). 
 
Other secondary outcomes 
There was a significant difference at two years in favour of the intervention group for the ICIQ-UI SF 
score, which combines urine leakage frequency, amount and associated bother (mean difference 
−0·83, 95% CI −1·44 to −0·22, p=0·008). No significant difference was found however between the 
groups in the percentage who experienced any urine leakage or severe incontinence at two years, or 
the number of pads used weekly (Table 7). Faecal urgency and leakage were not significantly 
different between groups at two years, but interference associated with bowel symptoms was less in 
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 the intervention group (mean difference −0·51 (95% CI −0·96 to −0·06), p=0·026). Sexual symptoms 
did not differ between groups at two years (Table 7). There were greater lifestyle changes in the 
intervention group in terms of women reducing heavy lifting, changing the way they exercise and 
attending exercise classes (Table 8). 
 
Economic outcomes 
Cost per QALY was calculated using only the UK data. Cost of the intervention for year 1 includes 
cost of five physiotherapy appointments, initial appointment letter, prolapse lifestyle advice leaflet, 
six Pilates-based classes, and physiotherapy review appointment. It is assumed that each woman 
attends all appointments and classes. The cost of the intervention was calculated at £519 per year 
for one woman taking part. The control cost was £1 for the prolapse lifestyle advice leaflet. Thus, at 
year 1, the incremental cost of the intervention is £518. Taking into account savings due to 
intervention group women having significantly fewer GP contacts relating to prolapse, the adjusted 
incremental cost is £514. There were no significant differences between groups in the SF-6D score at 
one year (mean difference 0.01 (95% CI −0.01 to 0.04), p=0.351) or 2 year (mean difference −0.01 
(95% CI −0.04 to 0.02), p=0.548). The incremental QALYs at year 1 are 0.02. Dividing the incremental 
cost by the incremental QALYs gives a cost per QALY of £21,996. At year 2, the incremental cost of 
the intervention is £329 (one physiotherapy review appointment plus six classes in year 2) and the 
incremental QALYs are 0.01, giving a cost per QALY of £29,409. 
 
Discussion  
Main findings 
The prolapse symptom score was less at two years in women randomised to the PFMT intervention. 
The control group mean symptom score had stayed similar over the study time-points, whereas the 
intervention group score had decreased (indicating fewer symptoms on average). The difference 
between the groups was one point in the POP-SS, but this was less than the minimal clinically 
important difference for the POP-SS of 1·521. However this MCID value was derived from data on 
women having surgery for prolapse, and arguably women who are less symptomatic may value a 
smaller improvement. This assertion is supported by the fact that women in the intervention group 
were more likely than controls to say they felt a health-related benefit due to the study. Urinary 
incontinence severity and interference due to bowel symptoms were also significantly less in the 
intervention group at two years, suggesting additional clinical benefit was gained. There were no 
differences in the results by sub-group, suggesting that the woman’s age, stage of prolapse and 
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 prolapse leading edge did not alter the intervention effect. Economic analysis suggests such an 
intervention could be cost-effective, although cost per QALY ranged from £21,996 in year 1 to 
£29,409 in year 2, exceeding NICE-recommended cost-effectiveness threshold of £20,000 
(https://www.nice.org.uk/article/pmg6/chapter/7-assessing-cost-effectiveness#/economic-
evidence-and-guideline-recommendations). However, cost-effectiveness may be increased by future 
savings from reduced use of healthcare for prolapse symptoms in the intervention group. Further 
follow-up to determine long-term benefits is planned. 
Strengths and limitations 
The main strengths of this trial were its size, internationality, and pragmatic efficient design, which 
utilised an existing cohort of women to identify potentially suitable participants. It provides 
important evidence relevant to women who are at risk of prolapse, a growing number due to the 
ageing population. Our trial was also woman-centred, with participant-reported symptoms as the 
primary outcome. 
We included women based on their POP-Q stage and absence of previous prolapse treatment, 
regardless of whether they reported symptoms on the POP-SS. The combination of POP-Q stage and 
previous treatment was the most objective way to identify women at risk of prolapse progression, 
given that there are no normative data for the POP-SS to suggest a threshold which would be 
considered symptomatic. Twenty percent of participants, distributed equally across groups, had a 
baseline POP-SS of zero, but had stage I, II or III prolapse and had not sought treatment. A post-hoc 
sensitivity analysis removing these women increased the intervention effect size slightly but would 
not change the conclusions of the trial. 
 
The difference between the UK and NZ timing of pre-trial prolapse assessment was a limitation. The 
majority of UK women had a POP-Q assessment between 25 and 57 months prior to the trial, whilst 
all NZ women had a POP-Q immediately prior to trial entry. This POP-Q information was used, along 
with baseline questionnaire responses, to determine trial eligibility. It is possible that a UK woman’s 
stage of prolapse had changed in the intervening period, either improving or getting worse22, 
however, such women should be equally distributed between the two groups due to randomisation. 
Moreover, from analysis of the NZ POP-Q data, no woman’s prolapse stage changed between the 12 
year follow-up time-point and trial entry to either a stage 0 or stage IV, meaning eligibility was not 
affected, and offering reassurance that this is likely to be true also for UK women. 
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 An unavoidable limitation was the lack of blinding of the women participating. The implications of 
unmasked participants are that women may have been more positive/negative in their responses in 
the knowledge that they were in the intervention/control group respectively. However in a 
prevention trial this is less problematic than in a treatment trial since women recruited are not 
seeking treatment and therefore may be less likely to feel that they have been disadvantaged by 
being in the control group. We provided control group women with a prolapse lifestyle advice leaflet 
which they would not otherwise have received in an attempt to minimise this possibility further.  
The intervention group women may have felt they were at an advantage because they knew they 
were having treatment over and above normal care, and we recognise this may have impacted on 
their responses. Unfortunately the nature of the intervention makes it impossible to avoid such 
performance bias. 
 
Interpretation of findings in context of other research 
The last decade has seen a growth in the evidence-base relating to PFMT for prolapse, however 
most trials relate to treatment of established symptomatic prolapse in clinical populations.23 The 
largest, high quality trials have found PFMT compared to no treatment is effective in reducing 
prolapse symptoms in women with stage I to III prolapse.7,8 Recently other trials of varying size and 
quality have compared PFMT with active controls such as lifestyle interventions 24, Pilates 25, fitness 
program 26, or other forms of PFMT 27,28,29. Again these trials have reported benefits from PFMT, 
although in some cases the active controls have appeared to do equally well.24,25,29 
No trial had targeted prolapse prevention prior to PREVPROL commencing. In 2013, Bø published on 
175 primiparous women after vaginal delivery to a singleton infant, selected irrespective of whether 
they had prolapse signs, randomised to supervised PFMT or written PFMT advice (control).30 The 
intervention group attended weekly PFMT classes for four months, and performed home-based 
exercise, while controls had no supervision. At six months post-partum there was no difference 
between groups in the prevalence of bulging either inside or outside the vagina, nor in stage II 
prolapse. Due to the difference in populations between this trial and PREVPROL, the findings are not 
comparable. In a 2016 trial in 287 primary care older women (mean age 64) with symptomatic mild 
prolapse (above the hymen), Panman31 randomised women to PFMT or watchful waiting. Women in 
the PFMT group were given an explanation of pelvic floor anatomy and dysfunctions, were taught 
“the Knack”32, given lifestyle advice, and had visits with the pelvic physiotherapist weekly initially, 
then at extended intervals. Home PFMT was recommended three to five times a week, twice or 
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 three times each day. Similar to our findings, at two years women in the intervention group 
improved their symptom score significantly more than those in the watchful waiting group, and 
were more likely to report overall symptom improvement. 
 
Implementation 
Although women in our trial had not been seeking treatment, uptake of PFMT appointments was 
91%, around half attended for annual reviews, over half had made at least one lifestyle change to 
reduce risk of prolapse, and 77% reported undertaking PFM exercises at two years, suggesting 
willingness to engage with a prevention intervention. Generalisability of the findings is important to 
consider however, as we might expect lower uptake than that observed in the trial if the 
intervention was rolled out to women in the general population. 
 
There was lower uptake of the exercise classes (28% Year 1 and 15% Year 2), which were intended to 
support long-term adherence to PFMT, known to decrease with time. This suggests that the effect of 
the intervention may be due to its one-to-one components (physiotherapy appointments, prescribed 
home exercise, and lifestyle discussions). We cannot however say with certainty which part or parts 
of this complex intervention contributed to the effect observed. This would require further trials 
targeting individual or combined elements of the intervention. 
 
The optimal “dose” and delivery mode of PFMT for this population is something that requires further 
research. To reduce the burden for women and costs to the health service we would want to know 
how much physiotherapist contact and supervision is required to achieve sufficient symptom 
management and avoidance of more invasive treatments, such as pessaries or surgery. 
 
Conclusions 
We provide evidence that PFMT leads to a small, but likely important reduction in prolapse 
symptoms, in women with stage I to III prolapse who have not previously sought prolapse 
treatment. Evidence was also found in the intervention group of less urinary incontinence, less 
interference due to bowel symptoms, and lower uptake of prolapse treatment. This is important 
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 information for physiotherapists, gynaecologists, and women generally, to inform decisions about 
adopting preventive strategies. (word count 3822) 
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 Figures and tables 
Figure 1. 
Invited to participate in PREVPROL trial 1130 
Responded 544 
   Eligible (based on questionnaire response and 12 year POP-Q) 297 
   Excluded (based on questionnaire response) 60 
      Previous treatment for prolapse (surgery, pessary, PFMT) 23 
      Previous incontinence surgery (except mid-urethral sling operation) 11 
      Previous formal instruction in PFMT for any diagnosis in preceding five years 9 
      Unwilling/unable to participate 
      Other 
15 
2 
      Reason for ineligibility not known 15 
   Further examination 
      Did not attend appointment for further examination 
187 
53 
      Unwilling to participate (following examination) 1 
      Ineligible (based on POP-Q Stage 0 at examination) 16 
      Eligible (based on POP-Q at examination) 117 
 
      
 Eligible and agreed                                                                             414 
            
Randomised 414 
            
Intervention n = 207     Control n = 207 
1 post-randomisation exclusion  
(previous physiotherapy) 
 206 included in analysis 
    1 post-randomisation exclusion  
(POP-Q stage 0) 
206 included in analysis     
            
Baseline questionnaire 206/206 (100%)     Baseline questionnaire 206/206 (100%) 
            
-    Physiotherapist one-to-one*:  
o 1 or more appointments: 183/202 (91%) 
o 3 or more appointments: 149/202 (74%) 
o all 5 appointments: 88/202 (44%) 
    
-    Physiotherapist one-to-one:  
o 1 or more appointments: 0 (0%) 
o 3 or more appointments: 0 (0%) 
o all 5 appointments: 0 (0%) 
-    Classes     -    Classes 
  o  Block 1: 58/206 (28%)       o  Block 1: 0 (0%) 
  o  Block 2: 31/206 (15%)       o  Block 2: 0 (0%) 
-    Annual review     -    Annual review 
  o  Attended Year 1: 107/206 (52%)       o  Attended Year 1: 0 (0%) 
  o  Attended Year 2: 93/206 (45%)       o  Attended Year 2: 0 (0%) 
            
One year questionnaire 161/206 (78%)     One year questionnaire 165/206 (80%) 
            
Two year questionnaire 163/206 (79%)     Two year questionnaire 182/206 (88%) 
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 * forms missing for 4 women 
Table 1. Baseline characteristics of randomised women 
 Intervention 
N=206  
Control  
N=206 
Centre -n (%)   
 Dunedin, NZ 39 (18·9%) 38 (18·4%) 
 Birmingham, UK 66 (32·0%) 66 (32·0%) 
 Aberdeen, UK 101 (49·0%) 102 (49·5%) 
Age in years -mean (SD) 46·4 (4·7)  46·6 (4·6) 
            -median (range) 46·5 (33 – 61) 47·0 (31 – 59) 
Parity  -median (range) 2 (1 – 11) 2 (1 – 8) 
 1 18 (8.7%) 25 (12.1%) 
 2 107 (51.9%) 101 (49.0%) 
 3 56 (27.2%) 56 (27.1%) 
 >3 25 (12.1%) 24 (11.7%) 
Method of delivery -n (%)   
 SVDs only 92 (44·7%) 83 (40·3%) 
 CS only 17 (8·3%) 19 ( 9·2%) 
 Any forceps 47 (22·8%) 54 (26·2%) 
 Any vacuum no forceps 20 ( 9·7%) 16 ( 7·8%) 
 CS+SVDs 30 (14·6%) 34 (16·5%) 
Stage of prolapse -n (%) 
I/II above or at the hymen 
I 
II above or at the hymen 
II beyond the hymen 
III  
 
199 (96·6%) 
90 (43·7%) 
109 (52·9%) 
6 ( 2·9%) 
1 ( 0·5%) 
 
200 (97·1%) 
96 (46·6%) 
104 (50·5%) 
6 ( 2·9%) 
0 ( 0·0%) 
Leading edge of prolapse -n (%)   
       Anterior only 101 (49·0%) 97 (47·1%) 
       Posterior only 41 (19·9%) 44 (21·4%) 
       Anterior + posterior 64 (31·1%) 63 (30·6%) 
       Anterior + posterior + vault 0 (0·0%) 1 (0·5%) 
       Not known 0 1 
Duration of prolapse symptoms (months) -mean (SD) 33·3 (52·9) 36·2 (54·3) 
Baseline POP-SS score -mean (SD) 4·4 (4·5) 3·9 (3·7) 
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 Baseline POP-SS score = 0 – n (%) 41 (19.9%) 40 (19.4%) 
SVD=spontaneous vaginal delivery 
CS=caesarean section 
POP-SS=pelvic organ prolapse symptom score 
SD=standard deviation 
 
Table 2 Prolapse symptoms (POP-SS score) reported in baseline, Year 1 and Year 2 questionnaires 
 Baseline Year 1  Year 2  
POP-SS* PFMT 
N=206 
 
control 
N=206  
 
PFMT 
N=159 
Control 
N=164 
Effect size#  
(95% CI) 
p-value 
PFMT 
N=161 
control 
N=180 
Effect size# 
(95% CI) 
p-value 
Mean  
(SD) 
4·4  
(4·5) 
3·9  
(3·7) 
3·2  
(3·5) 
3·9  
(3·7) 
-0·98 
(-1·61, -0·35) 
p=0·002 
3·2  
(3·4) 
4·2  
(4·4) 
-1·01  
(-1·70, -0·33),  
p=0·004 Median  
(range) 
3  
(0-26) 
3  
(0-17) 
2  
(0-19) 
3  
(0-17) 
2  
(0-22) 
3  
(0-27) 
POP-SS=0 
N (%) 
41 
(19.9%) 
40 
(19.4%) 
41 
(25.8%) 
27 
(16.5%) 
 35 
(21.7%) 
36 
(20%) 
 
*POP-SS score, 0=no symptoms, 28 = all symptoms all the time 
#Estimated effect of intervention on POP-SS (from repeated measures model) 
 
Table 3 Comparison between groups of each POP-SS symptom at 2 years 
Symptom at year 2 OR* 95% CI p-value 
Something coming down 0·40 0·23 0·73 0·002 
Discomfort worse when standing 0·71 0·33 1·51 0·374 
Abdominal pain when standing 0·60 0·36 1·01 0·056 
Lower back heaviness 0·63 0·37 1·05 0·076 
Strain to empty bladder 0·41 0·24 0·69 0·001 
Feel bladder not empty 0·65 0·42 1·01 0·058 
Feel bowel not empty 0·89 0·58 1·36 0·587 
 
*Odds ratios from the ordinal regression model of less than 
one favour the intervention group 
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 Table 4 Individual prolapse symptoms reported in baseline, Year 1 and Year 2 questionnaires  
  
Intervention Control 
Baseline Year 1 Year 2 Baseline Year 1 Year 2 
Prolapse symptom   N=206 N=161 N=163 N=206  N=165 N=182 
Something coming down Score - mean (SD) 0·4 (0·7) 0·3 (0·6) 0·2 (0·6) 0·3 (0·7) 0·3 (0·6) 0·4 (0·8) 
Any symptom - n (%) 55 (26·7%)  32 (19·9%)   27 (16·6%)  50 (25·1%)  42 (25·5%)   52 (28·6%)  
Most or all the time - n (%) 5 (2·4%)  3 (1·9%)   3 (1·8%)  1 (0·5%)  2 (1·2%)   5 (2·8%)  
Discomfort worse when standing Score - mean (SD) 0·3 (0·6) 0·1 (0·5) 0·1 (0·4) 0·2 (0·5) 0·2 (0·5) 0·2 (0·6) 
Any symptom - n (%) 42 (20·4%)  16 (9·9%)   17 (10·4%)  34 (17·1%)  27 (16·4%)   24 (13·2%)  
Most or all the time - n (%) 2 (1·0%)  1 (0·6%)   0 (0·0%)  0 (0·0%)  1 (0·6%)   3 (1·7%)  
Abdominal pain when standing Score - mean (SD) 0·6 (0·8) 0·3 (0·6) 0·3 (0·6) 0·4 (0·7) 0·4 (0·7) 0·4 (0·8) 
Any symptom - n (%) 86 (41·8%)  39 (24·2%)   47 (28·8%)  64 (32·2%)  54 (32·7%)   57 (31·3%)  
Most or all the time - n (%) 5 (2·4%)  2 (1·2%)   5 (2·8%)  3 (1·5%)  3 (1·8%)   6 (0·0%)  
Lower back heaviness  Score - mean (SD) 0·6 (0·9) 0·4 (0·7) 0·4 (0·8) 0·4 (0·8) 0·4 (0·7) 0·5 (0·9) 
Any symptom - n (%) 70 (34·0%)  45 (28·0%)   45 (27·6%)  61 (30·7%)  54 (32·7%)   63 (34·6%)  
Most or all the time - n (%) 9 (4·4%)  2 (1·2%)   5 (3·1%)  4 (2·0%)  2 (1·2%)   9 (5·0%)  
Strain to empty bladder Score - mean (SD) 0·6 (0·9) 0·5 (0·8) 0·4 (0·8) 0·6 (0·9) 0·7 (0·9) 0·7 (0·9) 
Any symptom - n (%) 84 (40·8%)  55 (34·2%)   44 (27·0%)  80 (40·2%)  74 (44·9%)   73 (40·6%)  
Most or all the time - n (%) 13 (6·3%)  3 (1·9%)   5 (3·1%)  10 (5·0%)  7 (4·2%)   10 (5·5%)  
Feel bladder not empty Score - mean (SD) 0·8 (1·0) 0·6 (0·8) 0·6 (0·8) 0·8 (0·9) 0·9 (0·9) 0·9 (0·9) 
Any symptom - n (%) 107  72 (44·7%)   75 (46·0%)  111  93 (56·4%)   103 
19 
 
 (51·9%) (55·8%) (56·6%)  
Most or all the time - n (%) 17 (8·3%)  4 (2·5%)   5 (3·1%)  13 (6·5%)  11 (6·7%)   14 (7·7%)  
Feel bowel not empty Score - mean (SD) 1·1 (1·0) 0·9 (0·9) 1·0 (0·9) 1·0 (1·0) 0·9 (0·9) 1·0 (1·0) 
Any symptom - n (%) 
139 
(67·5%) 
 93 (57·8%)  
 106 
(65·0%)  
128 
(64·3%) 
 102 
(61·8%)  
 115 
(63·2%)  
Most or all the time - n (%) 17 (8·3%)  9 (5·6%)   7 (4·3%)  14 (7·0%)  10 (6·1%)   14 (7·7%)  
 
Table 5 Summary of prolapse-related quality of life scores in baseline and Year 2 questionnaires (N, mean, SD) 
 Baseline Year 2 
Mean difference at 2 years 
Quality of Life* Intervention Control Intervention Control 
Prolapse interferes with physical activity 
N=194 
0.8 (2.1) 
N=194 
0.6 (1.7) 
N=166 
0.6 (1.6) 
N=178 
0.8 (1.9) 
-0.18 (95% CI -0.51 to 0.15), p=0.286 
Prolapse interferes with social activity 
N=191 
0.5 (1.6) 
N=195 
0.5 (1.6) 
N=166 
0.4 (1.4) 
N=178 
0.5 (1.6) 
 0.01 (95% CI -0.25 to 0.28), p=0.915 
Prolapse interferes with personal hygiene 
N=192 
0.6 (1.8) 
N=195 
0.7 (1.9) 
N=166 
0.5 (1.3) 
N=178 
0.6 (1.7) 
-0.06 (95% CI -0.35 to 0.23), p=0.679 
Prolapse interferes with everyday life 
N=193 
0.8 (1.9) 
N=195 
0.6 (1.6) 
N=166 
0.5 (1.4) 
N=178 
0.7 (1.7) 
-0.13 (95% CI -0.41 to 0.14), p=0.344 
*Each item response ranges from 0 “not at all” to 10 “a great deal”, or “not applicable”. If “not-applicable”, then the score is assumed to be zero. 
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Table 6 Uptake of treatment for prolapse symptoms (during year 1 and year 2 of follow-up)  
 In Year 1 In Year 2 Within 2 years 
 
Intervention 
n/N (%) 
Control 
n/N (%) 
Intervention 
n/N (%) 
Control 
n/N (%) 
Intervention 
n/N (%) 
Control 
n/N (%) 
Odds ratio4 
(95% CI), p-value 
ANY TREATMENT1 4/158 (2·5%) 13/163 (8·0%) 10/164 (6·1%) 17/176 (10·2%) 8/135 (5·9%) 22/153 (14·4%) 0·29 (95% CI 0·12 to 0·71), p=0·007 
Surgery2 0/153 (0·0%) 1/153 (0·7%) 0/163 (0·0%) 1/171 (0·6%) 0/131 (0·0%) 1/143 (0·7%) n/a 
Pessary2 0/158 (0·0%) 0/163 (0·0%) 0/164 (0·0%) 2/175 (1·1%) 0/135 (0·0%) 2/153 (1·3%) n/a 
Physio referral 0/124 (0·0%) 5/134 (3·7%) 4/162 (2·5%) 8/170 (4·7%) 1/108 (0·9%) 7/125 (5·6%) 0·14 (95% CI 0·02 to 1·20), p=0·074 
Practice nurse 0/126 (0·0%) 1/137 (0·7%) 4/161 (2·5%) 7/173 (4·0%) 2/110 (1·8%) 5/128 (3·9%) 0·37 (95% CI 0·07 to 2·05), p=0·257 
Continence nurse 0/122 (0·0%) 1/130 (0·8%) 3/161 (1·9%) 1/169 (0·6%) 0/106 (0·0%) 0/121 (0·0%) n/a 
GP 2/126 (1·6%) 8/140 (5·7%) 8/158 (5·1%) 17/176 (9·7%) 3/105 (2·9%) 16/131 (12·2%) 0·19 (95% CI 0·05 to 0·67), p=0·010 
Gynaecologist 0/110 (0·0%) 2/124 (1·6%) 2/147 (1·4%) 3/159 (1·9%) 2/97 (2·1%) 3/116 (2·6%) 0·74 (95% CI 0·12 to 4·64), p=0·750 
Other treatment3 1/110 (0·9%) 2/124 (1·6%) 0/147 (0·0%) 1/159 (0·6%) 1/97 (1·0%) 2/116 (1·7%) 0·95 (95% CI 0·07 to 12·12), p=0·965 
Not specified 1/110 (0·9%) 0/124 (0·0%) 4/147 (2·7%) 0/159 (0·0%) 2/97 (2·0%) 0/116 (0·0%) n/a 
1At one year the odds ratio for any treatment is 0·40 (95% CI 0·14 to 1·17), p=0·095, and at two years the odds ratio is 0·49 (95% CI 0·21 to 1·12), p=0·090. 2Only surgery and pessary were included in the NZ 
questionnaire at one year. 3In the first year, a woman in the intervention group had PFMT, a woman in the control group had laxatives to empty her bowel because of her prolapse, and another woman in the control 
group had counselling. In the second year, a woman in the control group had PFMT. 4Not analysed if there are any zero event rates. 
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 Table 7  Urinary, bowel and sexual symptoms reported in baseline and year 2 questionnaires  
 Baseline Year 2 Difference at 2 years 
 Intervention Control Intervention Control  
Urinary symptoms      
ICIQ UI SF score* 
 - mean (SD) 
4·8 (4·1) 
N=202 
4·2 (3·9) 
N=194 
3·3 (3·3) 
N=161 
4·1 (4·1) 
N=175 
Mean difference -0·83  
(95% CI -1·44 to -0·22), p=0·008 
Any incontinence 
 - n/N (%) 
150/205 
(73·2%) 
137/198 
(69·2%) 
107/163 
(65·6%) 
124/176 
(70·5%) 
OR=0·62  
(95% CI 0·33 to 1·15), p=0·128 
Severe incontinence (ICIQ UI 
SF score>=13) - n/N (%) 
13/202 
(6·4%) 
6/194 
(3·1%) 
3/161 
(1·9%) 
10/175 
(5·7%) 
OR=0·23 
(95% CI 0·05 to 1·06), p=0·059 
No· of pads per week for those 
that use pads - mean (SD)  
9·2 (5·7) 
N=36 
7·4 (7·7) 
N=41 
8·5 (5·8) 
N=39 
7·4 (7·7) 
N=48 
Mean difference 0·52 
(95% CI -1·81 to 2·85), p=0·653 
Bowel symptoms      
Faecal urgency (any#) 
 - n/N (%) 
126/204 
(61·8%) 
116/199 
(58·3%) 
92/164 
(56·1%) 
96/176 
(54·5%) 
OR=1·06  
(95% CI 0·61 to 1·86), p=0·835 
Faecal urgency  
(most/all of the time) - n/N (%) 
9/204 
(4·4%) 
8/199 
(4·0%) 
5/164 
(3·0%) 
9/176 
(5·1%) 
OR=0·64  
(95% CI 0·19 to 2·13), p=0·465 
Faecal incontinence (any#) 
 - n/N (%) 
39/204 
(19·1%) 
43/194 
(22·2%) 
32/165 
(19·4%) 
41/177 
(23·2%) 
OR=0·74  
(95% CI 0·37 to 1·47), p=0·388 
     Passive FI - n/N (%) 33/204 
(16·2%) 
35/194 
(18·0%) 
26/164 
(15·9%) 
32/176 
(18·2%) 
OR=0·79  
(95% CI 0·39 to 1·56), p=0·493 
     Active FI - n/N (%) 6/204 
(2·9%) 
8/194 
(4·1%) 
5/164 
(3·0%) 
9/176 
(5·1%) 
OR=0·76 
(95% CI 0·21 to 2·75), p=0·675 
Faecal incontinence (severe##) 
 - n/N (%) 
8/204 
(3·9%) 
9/194 
(4·6%) 
7/165 
(4·2%) 
10/177 
(5·6%) 
OR=0·97  
(95% CI 0·31 to 3·01), p=0·959 
Bowel symptoms interfere 
with everyday life **– mean 
(SD) 
1·4 (2·0) 
N=164  
 
1.3 (1·9) 
N=150 
1·1 (1·6) 
N=131 
1·5 (2·4) 
N=137 
Mean difference -0·51  
(95% CI -0·96 to -0·06), 
p=0·026 
Sexual symptoms      
Sexually inactive due to 
prolapse - n/N (%) 
1/205 
(0·5%) 
1/199 
(0·5%) 
5/162 
(3·1%) 
9/177 
(5·1%) 
OR=0·71 
(95% CI 0·24 to 2·16), p=0·548 
22 
 
 PISQ-12 sexual function score$ 
- mean (SD) 
36·4 (5·9) 
N=168 
36·6 (6·1) 
N=158 
38·7 (4·4) 
N=128 
38·4 (5·0) 
N=134 
Mean difference=0·38  
(95% CI -0·44 to 1·20), p=0·363 
Prolapse symptoms interfere 
with sex life$$ - n/N (%) 
26/159 
(16·4%) 
24/152 
(15·8%) 
25/148 
(16·7%) 
32/162 
(19·8%) 
OR=0·66  
(95% CI 0·31 to 1·41), p=0·283 
 
*ICIQ UI SF score, 0=none, no interference with life to 21=maximum score. Women with no leakage were given a score of 
zero. 
** ranges from 0 “not at all” to 10 “a great deal” 
#occasionally/sometimes/most of the time/all of the time 
##sometimes/most of the time/all of the time 
$potential range from 0 to 48, higher score indicates greater sexual dysfunction 
$$a little/somewhat/a lot 
 
 
 
Table 8: Lifestyle changes 
 Year 2 Difference at 2 years 
 Intervention 
n (%) 
Control 
n (%) 
Lost weight 40/156 
(25·6%) 
48/163 
(29·4%) 
OR=0·66  
(95% CI 0·38 to 1·13), p=0·127 
Avoided/reduced heavy 
lifting 
55/155 
(35·5%) 
32/157 
(20·4%) 
OR=1·96  
(95% CI 1·13 to 3·39), p=0·017 
Changed the way you 
exercise 
68/148 
(45·9%) 
52/149 
(34·9%) 
OR=1·68  
(95% CI 1·01 to 2·80), p=0·046 
Attended exercise class 95/163 
(58.3%) 
75/174 
(43.1%) 
OR=2.25  
(95% CI 1.40 to 3.60), p=0·001 
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Putting research into context 
 
Research in context 
Evidence before this study 
The lead author is also author of the Cochrane review of conservative prevention and management 
of prolapse. The review, first published in 2006, found no prevention trials, which informed our 
decision to conduct the current research. The latest searches for this Cochrane review include a 
search of the Cochrane Incontinence Group Specialised Trials Register (10 September 2015) with the 
search strategy developed for the Cochrane Incontinence Review Group, and supplementary 
searches of CINAHL (from inception to 11 September 2015), PEDro (last searched September 2015), 
and ZETOC (12 September 2015) with the search terms: cystocele, urethrocele, rectocele, vault 
prolapse, uterine prolapse, vaginal prolapse, pelvic organ prolapse, pelvic floor. The reference lists of 
relevant articles were searched. No language or other restrictions were imposed in any of the 
searches. We have now identified one trial by Bø, in an early post-natal population of women, 
selected irrespective of whether they had prolapse,30 and another by Panman in an older population 
of women in primary care.31 The former (judged as low risk for selection, performance, detection, 
attrition and reporting bias, but unclear for other types of bias) found no benefit at 6 months but 
was not directly comparable. The latter (judged as low risk for all types of bias), which is more 
comparable to the current trial found a symptom benefit at 2 years.  
Added value of this study 
PREVPROL is the largest trial of PFMT for prevention of prolapse and the only one in women with 
signs of prolapse several years after childbirth. Its results, showing that the intervention had 
significant symptom benefit, will be added to the Cochrane review currently being updated. Meta-
analysis of the primary outcomes from this trial (POP-SS at 2 year follow-up) and the Panman trial31 
(PFDI-20 at 2 year follow-up) indicated a significant symptom benefit (reduced symptom score) for 
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 women who had undertaken PFMT (pooled SMD is −0.23 (95% CI −0.40 to −0.07), p=0.005). 
Implications of all the available evidence 
PFMT can prevent prolapse symptoms at 2 years after intervention and may reduce the uptake of 
treatment. Therefore women should be recommended to undertake PFMT even before they have 
bothersome symptoms. We do not know the long-term benefits as yet, but given that PFMT is safe 
and can be performed easily by most women, this should be encouraged. Provision of one-to-one 
teaching of PFMT is needed to support women with prolapse prevention. Qualitative research is 
needed to find out from women’s perspectives what format a prevention intervention should take 
to maximise uptake and benefit. 
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